[1] |
RAWLA P, SUNKARA T, MURALIDHARAN P, et al. Update in global trends and aetiology of hepatocellular carcinoma[J]. Contemp Oncol (Pozn), 2018, 22(3): 141-150.
|
[2] |
XIAO Y, ZHANG H, MA Q, et al. YAP1-mediated pancreatic stellate cell activation inhibits pancreatic cancer cell proliferation[J]. Cancer Lett, 2019, 462: 51-60. DOI: 10.1016/j.canlet.2019.07.015
|
[3] |
LU T, LI Z, YANG Y, et al. The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer[J]. Cancer Lett, 2018, 423: 36-46. DOI: 10.1016/j.canlet.2018.02.015
|
[4] |
GUO L, CHEN Y, LUO J, et al. YAP1 overexpression is associated with poor prognosis of breast cancer patients and induces breast cancer cell growth by inhibiting PTEN[J]. FEBS Open Bio, 2019, 9(3): 437-445. DOI: 10.1002/2211-5463.12597
|
[5] |
HU Y, WANG S, WU X, et al. Chinese herbal medicine-derived compounds for cancer therapy: A focus on hepatocellular carcinoma[J]. J Ethnopharmacol, 2013, 149(3): 601-612. DOI: 10.1016/j.jep.2013.07.030
|
[6] |
LIU B, LIU L, ZANG A, et al. Tanshinone ⅡA inhibits proliferation and induces apoptosis of human nasopharyngeal carcinoma cells via p53-cyclin B1/CDC2[J]. Oncol Lett, 2019, 18(3): 3317-3322.
|
[7] |
GUO Y, LI Y, XIANG B, et al. Nutlin-3 plus tanshinone ⅡA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph+ ALL[J]. Biochem J, 2017, 474(24): 4153-4170. DOI: 10.1042/BCJ20170386
|
[8] |
XUE J, JIN X, WAN X, et al. Effects and mechanism of tanshinone Ⅱ A in proliferation, apoptosis, and migration of human colon cancer cells[J]. Med Sci Monit, 2019, 25: 4793-4800. DOI: 10.12659/MSM.914446
|
[9] |
FAIVRE S, RIMASSA L, FINN RS. Molecular therapies for HCC: Looking outside the box[J]. J Hepatol, 2020, 72(2): 342-352. DOI: 10.1016/j.jhep.2019.09.010
|
[10] |
KUDO M, FINN RS, QIN S, et al. Lenvatinib versus sorafenib B in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173. DOI: 10.1016/S0140-6736(18)30207-1
|
[11] |
CHO ES, KANG HE, KIM NH, et al. Therapeutic implications of cancer epithelial-mesenchymal transition (EMT)[J]. Arch Pharm Res, 2019, 42(1): 14-24. DOI: 10.1007/s12272-018-01108-7
|
[12] |
CHEN X, LI Y, LUO J, et al. Molecular mechanism of Hippo-YAP1/TAZ pathway in heart development, disease, and regeneration[J]. Front Physiol, 2020, 11: 389. DOI: 10.3389/fphys.2020.00389
|
[13] |
EGE N, DOWBAJ AM, JIANG M, et al. Quantitative analysis reveals that actin and Src-family kinases regulate nuclear YAP1 and its export[J]. Cell Syst, 2018, 6(6): 692-708. DOI: 10.1016/j.cels.2018.05.006
|